JP Morgan Healthcare Conference and Biotech Showcase
We know that there are significant hurdles for companies like yours striving to succeed in today’s high-stakes biopharma market. Syneos Health can help you maximize value, achieve your full asset potential and successfully navigate through these modern market realities.
By leveraging our resources and expertise spanning all clinical development, medical affairs and commercialization, you will be able to:
- Optimize clinical development processes through more informed trial design and RWE strategies
- Realize better pipeline portfolio management
- Build a clear picture of launch success that investors can get behind
Our experts will be on the ground in San Francisco during the JP Morgan Healthcare Conference, and Biotech Showcase: The Investor Conference for Innovators to discuss your specific asset challenges and how we can drive success across the asset development continuum, providing fit-for-purpose solutions with high-quality delivery.
Featured Presentations
LUNCHEON PLENARY PANEL | Removing Barriers: Healthcare Access and Equity for All
January 9 | 12-1:30pm PT
Jane Williams, MD, MPH, Vice President and Head, Neuroscience, Rare Disease and Pediatrics
PANEL | Investing for Commercial Success as an Emerging Company
January 8 | 4-5pm PT
Michael Sarshad, Managing Director, Commercial Advisory Group
PANEL | Dealmakers’ Intentions 2024
January 9 | 3:30-4:30pm PT
Neel Patel, Executive Managing Director, Consulting
Related Content
Want to learn more? Explore Insights Hub for our latest perspectives, subscribe to our podcast, or click the resources below:
BLOG | Internal R&D Versus Externalization: Which Pharma Strategy Yields Greater Success?
Investing for Launch Success: Tailoring Your Strategy for Europe
Let Me Count the Ways: How Gen AI Will Transform Clinical Trial Efficiencies
BLOG | Cell and Gene Therapy Sponsors Must Overcome Unique Hurdles to Realize Promise to Patients
2024 Health Trends | The Big Leap: The Reinvention of Life Science
COMING SOON! Dealmakers’ Intentions 2024